Houston Methodist Cypress Hospital

The trials here

What the 10 trials at this site are about, from their registry records.

Conditions

• Amyloidosis1 trial
• Bladder cancer1 trial
• Head and neck cancer1 trial
• Kidney cancer1 trial
• Lung cancer1 trial
• Multiple myeloma1 trial
• Ovarian cancer1 trial
• Pancreatic cancer1 trial
• Prostate cancer1 trial
• Triple-negative breast cancer1 trial

Phase

• Phase 38 trials
• Phase 21 trial
• Phase 2/31 trial

Status

• Recruiting8 trials
• Active, not recruiting1 trial
• Suspended1 trial

Lead sponsor

• National Cancer Institute (NCI)3 trials
• NRG Oncology3 trials
• Alliance for Clinical Trials in Oncology2 trials
• Canadian Cancer Trials Group1 trial
• SWOG Cancer Research Network1 trial

Running trials

• Recruiting

  A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer

  NCT06524544· Phase 3· National Cancer Institute (NCI)· Source

  Contact: Patrick E. Prath (principal investigator)

• Recruiting

  Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer

  NCT06958328· Phase 3· NRG Oncology· Source

  Contact: Kevin T. Tran (principal investigator)

• Recruiting

  Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response

  NCT06592924· Phase 3· Canadian Cancer Trials Group· Source

  Contact: Patrick E. Prath (principal investigator)

• Recruiting

  Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer

  NCT06661720· Phase 3· Alliance for Clinical Trials in Oncology· Source

  Contact: Patrick E. Prath (principal investigator)

• Recruiting

  Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis

  NCT06022939· Phase 3· SWOG Cancer Research Network· Source

  Contact: Carrie H. Yuen (principal investigator)

• Recruiting

  Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

  NCT05879926· Phase 3· NRG Oncology· Source

  Contact: Sindhu Nair (principal investigator)

• Recruiting

  Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

  NCT05812807· Phase 3· Alliance for Clinical Trials in Oncology· Source

  Contact: Kai Sun (principal investigator)

• Active, not recruiting

  Comparing Cisplatin Every Three Weeks to Cisplatin Weekly When Combined With Radiation for Patients With Advanced Head and Neck Cancer

  NCT05050162· Phase 2/3· NRG Oncology· Source

• Recruiting

  Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

  NCT04181060· Phase 3· National Cancer Institute (NCI)· Source

  Contact: Jun Zhang (principal investigator)

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Amyloidosis1 recruiting
• Bladder cancer1 recruiting
• Kidney cancer1 recruiting
• Lung cancer1 recruiting
• Ovarian cancer1 recruiting
• Pancreatic cancer1 recruiting
• Prostate cancer1 recruiting
• Triple-negative breast cancer1 recruiting